Eiger BioPharmaceuticals, Inc.
EIGRQ · OTC
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $25 | $28 | $23 | $15 |
| Short-Term Investments | $0 | $12 | $31 | $60 |
| Receivables | $2 | $1 | $4 | $4 |
| Inventory | $2 | $1 | $1 | $5 |
| Other Curr. Assets | $9 | $13 | $12 | $12 |
| Total Curr. Assets | $38 | $55 | $70 | $97 |
| Property Plant & Equip (Net) | $1 | $1 | $1 | $1 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $1 | $1 |
| Total NC Assets | $1 | $1 | $2 | $2 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $39 | $56 | $72 | $99 |
| Liabilities | – | – | – | – |
| Payables | $2 | $5 | $5 | $12 |
| Short-Term Debt | $41 | $0 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $2 | $2 | $2 | $2 |
| Other Curr. Liab. | $10 | $11 | $11 | $12 |
| Total Curr. Liab. | $53 | $17 | $17 | $24 |
| LT Debt | $0 | $41 | $40 | $40 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $0 | $41 | $40 | $40 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $53 | $57 | $57 | $64 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$512 | -$499 | -$481 | -$460 |
| AOCI | -$0 | -$0 | -$0 | -$0 |
| Other Equity | $498 | $497 | $496 | $495 |
| Total Equity | -$14 | -$2 | $15 | $35 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $39 | $56 | $72 | $99 |
| Net Debt | $16 | $13 | $18 | $25 |